Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Glembatumumab

Known as: Immunoglobulin G2, Anti-(Human Transmembrane Glycoprotein NMB (HGFIN) Extracellular Domain) Human Monoclonal CR011 Heavy Chain (133-215')-Disulfide with Human Monoclonal CR011 Kappa Light Chain, Dimer (221-221'':222-222'':225-225'':228- 228'')-Tetrakis, Immunoglobulin, Anti-(Human Glycoprotein NMB Extracellular Domain) (Human Monoclonal CR011 Heavy Chain), Disulfide with Human Monoclonal CR011 Gamma-2 Kappa-Chain, Dimer 
A human monoclonal antibody against transmembrane glycoprotein non-metastatic melanoma protein B (GPNMB). Glembatumumab binds to GPNMB on cancer… Expand
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

CR011
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
BACKGROUND Glembatumumab vedotin is an antibody-drug conjugate that produced preliminary clinical activity against advanced… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2016
2016
Identification of gamma-synuclein as a new PCBP1-interacting protein
Objectives: PolyC binding protein 1 (PCBP1) is a transcriptional regulator of human mu-opioid receptor (hMOR) gene in the CNS and… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
PURPOSE Glycoprotein NMB (gpNMB), a negative prognostic marker, is overexpressed in multiple tumor types. Glembatumumab vedotin… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
2014
2014
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
BACKGROUND Glembatumumab vedotin is an antibody-auristatin conjugate that targets cells expressing the transmembrane glycoprotein… Expand
Is this relevant?
2014
2014
Abstract 3984: Elucidating expression patterns of GPNMB and potential anti-tumor effects of the antibody-drug conjugate, glembatumumab vedotin (CDX-011) in human osteosarcoma primary samples and cell…
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Despite numerous clinical trials to improve outcomes for… Expand
Is this relevant?
2010
2010
Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Glembatumumab vedotin (CR-011-vc-MMAE) is a mAb-drug conjugate being developed by Celldex Therapeutics Inc for the treatment of… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Biochemical characterization of a Neisseria meningitidis polysialyltransferase reveals novel functional motifs in bacterial sialyltransferases
The extracellular polysaccharide capsule is an essential virulence factor of Neisseria meningitidis, a leading cause of severe… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
Role of human HGFIN/nmb in breast cancer
IntroductionHGFIN, previously identified as nmb, and its homolog osteoactivin are single transmembrane proteins that are… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1996
1996
Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats.
BACKGROUND Atracurium has four chiral centers and the marketed product is a mixture of ten optical and geometric isomers. Six of… Expand
Is this relevant?
1992
1992
[Plasma-membrane fluidity studies of murine neuroblastoma and malignant melanoma cells under irradiation].
Murine neuroblastoma (C-1300 NMB) and malignant melanoma (B16) cells were radiated in presence of radiopharmaceutics… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE